DSP216

DSP216 is a bifunctional Fc-fusion protein developed by KAHR Medical that simultaneously blocks HLA-G and CD47 signaling to reverse tumor suppressive effects mediated by tumor-associated macrophages. By targeting HLA-G, a non-classical MHC molecule overexpressed on tumors that inhibits innate and adaptive immunity via LILRB1/2 receptors, and CD47, the "don't eat me" signal via SIRPα, DSP216 promotes phagocytosis and immune activation against cancer cells. It originated from technology licensed from Thomas Jefferson University and is designed for tumor-selective dual checkpoint inhibition, with preclinical data supporting anti-tumor activity in cancer models.[1][3][4][7]

Other names

DSP-216 - KAHR MedicalDSP216 - KAHR MedicalDSP 216 - KAHR Medical